Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GDC-0810 Formulation and Food Effect in Healthy Females
NCT02722018Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brilanestrant in breast cancer (3 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Plasma Concentration at Day 3, Time to Reach Cmax at Day 3 and 6 more. Started Jan 2016; status: completed.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02722018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722018.